Tags

Type your tag names separated by a space and hit enter

BNT162b2 mRNA COVID-19 Vaccine: First Approval.
Drugs. 2021 Mar; 81(4):495-501.D

Abstract

BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. BNT162b2 encodes the SARS-CoV-2 spike protein, the expression of which elicits immune responses against the antigen in recipients. In early December 2020, BNT162b2 received a temporary emergency use authorization (EUA) in the UK and, subsequently, a series of approvals or authorizations for emergency use in Bahrain, Canada, Mexico, Saudi Arabia and the USA. Soon after, BNT162b2 received conditional marketing authorizations in Switzerland (19 December 2020) and the EU (21 December 2020) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older. BNT162b2 is administered intramuscularly in a two-dose regimen. This article summarizes the milestones in the development of BNT162b2 leading to these first approvals for the prevention of COVID-19.

Authors+Show Affiliations

Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33683637

Citation

Lamb, Yvette N.. "BNT162b2 mRNA COVID-19 Vaccine: First Approval." Drugs, vol. 81, no. 4, 2021, pp. 495-501.
Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81(4):495-501.
Lamb, Y. N. (2021). BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs, 81(4), 495-501. https://doi.org/10.1007/s40265-021-01480-7
Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81(4):495-501. PubMed PMID: 33683637.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BNT162b2 mRNA COVID-19 Vaccine: First Approval. A1 - Lamb,Yvette N, PY - 2021/3/9/pubmed PY - 2021/3/26/medline PY - 2021/3/8/entrez SP - 495 EP - 501 JF - Drugs JO - Drugs VL - 81 IS - 4 N2 - BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. BNT162b2 encodes the SARS-CoV-2 spike protein, the expression of which elicits immune responses against the antigen in recipients. In early December 2020, BNT162b2 received a temporary emergency use authorization (EUA) in the UK and, subsequently, a series of approvals or authorizations for emergency use in Bahrain, Canada, Mexico, Saudi Arabia and the USA. Soon after, BNT162b2 received conditional marketing authorizations in Switzerland (19 December 2020) and the EU (21 December 2020) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older. BNT162b2 is administered intramuscularly in a two-dose regimen. This article summarizes the milestones in the development of BNT162b2 leading to these first approvals for the prevention of COVID-19. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/33683637/BNT162b2_mRNA_COVID_19_Vaccine:_First_Approval_ L2 - https://dx.doi.org/10.1007/s40265-021-01480-7 DB - PRIME DP - Unbound Medicine ER -